Yüksel Ürün, Professor of Medical Oncology at Ankara University School of Medicine, shared an update from Summit Therapeutics, on X, adding:
“Ivonescimab beat pembrolizumab on overall survival in first-line PD-L1+ NSCLC!
Next chapter is longer follow-up from the separate global HARMONi study, including Western patients. Different trial. Different population. But critical for understanding geographic translatability.”
Quoting Summit Therapeutics:
“Ivonescimab Monotherapy Demonstrates a Statistically Significant and Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab.
PD-L1 High Expression Subgroup: Hazard Ratio = 0.58.”
This also can be interesting:
